Abstract: Kits, devices, systems, and methods are disclosed for the detection of SARS-CoV-2. The kits, devices, systems, and methods utilize two different pairs of polymerase amplification oligonucleotide primers. The first polymerase amplification oligonucleotide primer pair comprises an isolated forward oligonucleotide primer and an isolated reverse oligonucleotide primer for a portion of a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) or Helicase (Hel) gene sequence. The second polymerase amplification oligonucleotide primer pair comprises an isolated forward oligonucleotide primer and an isolated reverse oligonucleotide primer for a portion of a SARS-CoV-2 Envelope (E) gene sequence. The kits, devices, systems, and methods can specifically detect SARS-CoV-2 infection as well as infection with another Betacoronavirus.

Abstract: Kits, devices, systems, and methods are disclosed for use in recombinase polymerase amplification (RPA) assays for the detection of Anaplasma infections. In certain non-limiting embodiments, the assays can identify and discriminate between three Anaplasma species.

Abstract: In accordance with exemplary embodiments, apparatus and method for biologic sample rapid collection and recovery device, and convenient storage are provided. An exemplary embodiment includes an apparatus comprising a lateral flow technology device including at least a membrane configured to bind an analyte from a sample that flows through the lateral flow technology device, in which a selected portion of the membrane bound to the analyte when placed directly in an analysis system does not substantially inhibit analysis of the analyte. An elution protocol is not required to extract the analyte bound from the selected portion before placed directly in the analysis system.

Abstract: In accordance with exemplary embodiments, apparatus and method for biologic sample rapid collection and recovery device, and convenient storage are provided. An exemplary embodiment includes an apparatus comprising a lateral flow technology device including at least a membrane configured to bind an analyte from a sample that flows through the lateral flow technology device, in which a selected portion of the membrane bound to the analyte when placed directly in an analysis system does not substantially inhibit analysis of the analyte. An elution protocol is not required to extract the analyte bound from the selected portion before placed directly in the analysis system.